Tango Therapeutics, Inc.
TNGX
NASDAQ·Healthcare·Biotechnology·Mkt cap $3.7B
$22.52
▼ -1.05%
P/E
-26.49
Mkt Cap
$3.7B
52-Wk Range
$6.25–$34.39
52-Week Range
$6.25 - $34.39
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 230.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary synthetic lethal discovery platform targeting genetic cancer vulnerabilities
- Strategic partnership with Gilead Sciences for development and commercialization
- Focus on precision oncology with large addressable markets in genetically-defined cancers
- Experienced management team with deep oncology and biotechnology expertise
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Clinical advancement of TNG908 in MTAP-deleted cancers with significant market potential
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Falling
-27.2% over 3m
Quality
Excellent
High-growth business (53% revenue growth, 98% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying TNGX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 10, 2026
Reported EPS of -$0.37 vs -$0.32 consensus (-16.6% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-16.6%
Revenue trend · last 8Q
—
-24%
-17%
-84%
+364%
-100%
-100%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$11.6M
$4.1M
$5.4M
$3.2M
$53.8M
$0
$0
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
11 analysts · 82% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
82%
Hold
18%
Sell
0%
Median Price Target
$46.00
▲ +104.3% vs $22.52
Latest: Guggenheim · Aug 12, 2026
1 analyst covering
vs Industry
How TNGX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related